...

CCO Independent Conference Coverage

2007 Annual Meeting of the European Association for the Study of the Liver*

April 11-15, 2007 | Barcelona, Spain

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Expert Highlights

Listen to the experts quickly summarize the key issues in viral liver disease highlighted at the conference!

These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged on to the clinicaloptions.com site to listen to or download the mp3 files.

Adrian M. Di Bisceglie, MD, FACP headshot

Adrian M. Di Bisceglie, MD, FACP, discusses the top line HBV data presented at the meeting with particular focus on combination therapy and key outcomes in long-term follow-up of patients receiving peginterferon-based treatment. (4 minutes)

Download Audio
Kris V. Kowdley, MD, FACP headshot

Kris V. Kowdley, MD, FACP, discusses use of human albumin for the treatment of ascites and evaluation of liver stiffness scans to detect esophageal varices in HCV patients with advanced liver disease.
(4 minutes)

Download Audio
Karen L. Lindsay, MD, MMM headshot

Karen L. Lindsay, MD, MMM, discusses the key studies on anti-HCV agents and the future of combination HCV therapies including currently approved therapies, specifically targeted small molecule agents and other immunomodulatory agents in development. (11 minutes)

Download Audio

Advances in HBV Treatment: 2007

Track 1 of 3

Faculty:

Adrian M. Di Bisceglie, MD, FACPGeoffrey M. Dusheiko, MD, FCP(SA), FRCPDaniel Shouval, MD
  • Adrian M. Di Bisceglie, MD, FACP
  • Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
  • Daniel Shouval, MD

Clinical Updates in HCV Treatment

Track 2 of 3

Faculty:

Peter Ferenci, MDIra M. Jacobson, MDKaren L. Lindsay, MD, MMM
  • Peter Ferenci, MD
  • Ira M. Jacobson, MD
  • Karen L. Lindsay, MD, MMM

Highlight on Special Hepatic Issues and Populations

Track 3 of 3

Faculty:

Nezam H. Afdhal, MD, FRCPIKris V. Kowdley, MD, FACPJosep M. Llovet, MD
  • Nezam H. Afdhal, MD, FRCPI
  • Kris V. Kowdley, MD, FACP
  • Josep M. Llovet, MD
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Capsule Summary:

Rosiglitazone Appears Superior to Metformin at Improving Metabolic Control and Liver Histology in Patients With NAFLD

Effects of rosiglitazone in NAFLD population may be enhanced by combination with metformin.

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES